Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed.

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Two key objectives for Sanofi under Brandicourt are to have a successful debut for cholesterol-lowerer Praluent (alirocumab) and a successful defence of its diabetes franchise, a responsibility ...

Praluent (Alirocumab): Sanofi Praluent (Alirocumab) is a PCSK9 inhibitor used to lower LDL cholesterol in patients with Atherosclerotic Cardiovascular Disease (ASCVD) who are inadequately controlled ...

Please provide your email address to receive an email when new articles are posted on . AACE published its first updated guideline on the pharmacologic management of adults with dyslipidemia since ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 ...

1 Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 ...

Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating ...